InvestorQ : What is your view on the quarterly numbers of Aarti Drugs?
indhumathi Sayani made post

What is your view on the quarterly numbers of Aarti Drugs?

Answer
image
sara Kunju answered.
7 days ago
Follow

For the Q4FY22 ending in March 2022, Aarti Drugs reported a robust 38.4% growth in sales revenues at Rs694.27 crore on a consolidated basis. FY22 revenues for the 12 months were higher by 15.5% at Rs2,489 crore. The big top line driver was the growth in active pharma ingredients (APIs), which grew 46% with volumes growing 23% yoy. Formulations revenues grew more subdued at 7.8% while specialty chemicals were up 17%. Exports contributed 39% of the formulation revenues, although overall growth was tepid.

Aarti Drugs

Rs in Crore

Mar-22

Mar-21

YOY

Dec-21

QOQ

Total Income (Rs cr)

₹ 694.27

₹ 501.75

38.37%

₹ 634.80

9.37%

Net Profit (Rs cr)

₹ 55.34

₹ 51.65

7.14%

₹ 58.29

-5.06%

Diluted EPS (Rs)

₹ 5.97

₹ 5.54

₹ 6.29

Net Margins

7.97%

10.29%

9.18%

  

For the fourth quarter, Q4FY22, net profits were higher by 7.14% at Rs55.34 crore. The fall in profits can be largely attributed to the sharp spike in raw material costs. Q4FY22 EBITDA was up 9.1% at Rs89 crore while but the real villain of the piece was the EBITDA margins tapering to 351 basis points to 12.8% yoy. Net margins at 7.97% in Q4FY22 quarter was lower than the 10.29% in Q4FY21. The net cash flows got impacted by spike in trade receivables during the quarter.

3 Views